Literature DB >> 32956719

Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy.

Christian G Figueroa-Espada1, Samuel Hofbauer2, Michael J Mitchell3, Rachel S Riley4.   

Abstract

A major challenge to treating diseases during pregnancy is that small molecule therapeutics are transported through the placenta and incur toxicities to the developing fetus. The placenta is responsible for providing nutrients, removing waste, and protecting the fetus from toxic substances. Thus, the placenta acts as a biological barrier between the mother and fetus that can be exploited for drug delivery. Nanoparticle technologies provide the opportunity for safe drug delivery during pregnancy by controlling how therapeutics interact with the placenta. In this Review, we present nanoparticle drug delivery technologies specifically designed to exploit the placenta as a biological barrier to treat maternal, placental, or fetal diseases exclusively, while minimizing off-target toxicities. Further, we discuss opportunities, challenges, and future directions for implementing drug delivery technologies during pregnancy.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Active targeting; Drug delivery technologies; Nanoparticle; Placenta; Pre-eclampsia; Pregnancy

Year:  2020        PMID: 32956719     DOI: 10.1016/j.addr.2020.09.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  2 in total

1.  Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery.

Authors:  Kelsey L Swingle; Margaret M Billingsley; Sourav K Bose; Brandon White; Rohan Palanki; Apeksha Dave; Savan K Patel; Ningqiang Gong; Alex G Hamilton; Mohamad-Gabriel Alameh; Drew Weissman; William H Peranteau; Michael J Mitchell
Journal:  J Control Release       Date:  2021-11-03       Impact factor: 9.776

Review 2.  Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.

Authors:  Anjali Sharma; Nirnath Sah; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2021-08-26       Impact factor: 17.873

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.